Acuta Capital Partners’s Revolution Medicines RVMD Stock Holding History

Acuta Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54M	Buy	26,069 +17,658	+210%	+$1.78M	1.79%	15
2025 Q4	$670K	Hold	8,411	–	–	0.45%	26
2025 Q3	$393K	Sell	8,411 -47,282	-85%	-$1.85M	0.41%	26
2025 Q2	$2.05M	Sell	55,693 -10,969	-16%	-$421K	2.86%	13
2025 Q1	$2.36M	Sell	66,662 -45,038	-40%	-$1.83M	2.73%	13
2024 Q4	$4.89M	Buy	111,700 +3,700	+3%	+$187K	4.92%	8
2024 Q3	$4.9M	Sell	108,000 -25,000	-19%	-$1.09M	3.97%	9
2024 Q2	$5.16M	Sell	133,000 -10,777	-7%	-$403K	4.35%	9
2024 Q1	$4.63M	Sell	143,777 -16,223	-10%	-$481K	3.01%	13
2023 Q4	$4.59M	Buy	+160,000	New	+$3.84M	2.58%	17

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acuta Capital Partners's RVMD Position: Q1 2026 in Review

Acuta Capital Partners increased its Revolution Medicines (RVMD) stake by 210% in Q1 2026, buying an estimated $1.78M and bringing the position to 26,069 shares worth $2.54M. The position accounts for 1.79% of the portfolio, ranked #15.

Acuta Capital Partners first reported a position in RVMD in Q4 2023 and has held it in 10 quarters since. The position peaked at $5.16M in Q2 2024. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

Acuta Capital Partners held 26,069 shares of Revolution Medicines worth $2.54M as of Q1 2026.
Acuta Capital Partners bought 17,658 Revolution Medicines shares in Q1 2026, an estimated $1.78M.
Revolution Medicines made up 1.79% of Acuta Capital Partners's portfolio in Q1 2026, its #15 holding.
Acuta Capital Partners first reported a position in Revolution Medicines in Q4 2023 and has held it in 10 quarters since.
Acuta Capital Partners's Revolution Medicines position peaked at $5.16M in Q2 2024.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.